Abstract
Schizophrenia poses a significant economic burden on the healthcare system as well as it has a significant impact on society at large. Reasons for such a high economic burden of schizophrenia include the frequent relapses and hospitalizations occurring in this disorder. We analyze the effectiveness of long-acting injectable antipsychotics (LAIs) compared to oral medications, in terms of "clinical process management" in a sample of patients with a diagnosis of schizophrenia spectrum disorder treated in community mental health centers. An observational, retrospective, mirror-image study was carried out to evaluate the effectiveness of LAIs compared to oral medications in terms of number of hospitalizations, emergency visits and planned visits on a 10-year period (from July 2007 to June 2017). Differences between first and second generation LAIs were also explored. Our findings show that hospitalization and emergency visits are significantly decreased with the use of LAIs, while planned visits are increased in patients treated with LAIs. Our results suggest that LAIs, in particular, second generation ones, reduce hospitalization rates and emergency visits, improving the economic burden of schizophrenia. Therefore, LAIs should be c...Continue Reading
References
Jul 6, 2005·Archives of General Psychiatry·Jennifer C DayCheryl Power
May 3, 2006·The Journal of Clinical Psychiatry·Haya Ascher-SvanumJeff W Swanson
Feb 27, 2010·Psychiatry Research·Diego NovickPeter M Haddad
May 18, 2012·The Cochrane Database of Systematic Reviews·Stefan LeuchtJohn M Davis
Dec 22, 2012·Schizophrenia Bulletin·Taishiro KishimotoChristoph U Correll
Mar 14, 2013·Advances in Therapy·Steve OffordBruce Wong
May 15, 2013·Journal of Medical Economics·John M KaneTimothy Peters-Strickland
Jul 17, 2013·Patient Education and Counseling·Rosemarie McCabeStephen Bremner
Nov 16, 2013·The Journal of Clinical Psychiatry·Taishiro KishimotoChristoph U Correll
Feb 6, 2014·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Andrea FiorilloJulian Beezhold
Feb 14, 2014·BMJ : British Medical Journal·Elizabeth KuipersTim Kendall
May 21, 2014·Schizophrenia Research·Larry AlphsJohn Lauriello
Oct 29, 2015·Psychiatry Investigation·Seung Yup LeeJong-Woo Paik
Jan 26, 2017·Schizophrenia Research·Philippe D VincentViolaine Masson
Mar 31, 2017·Patient Preference and Adherence·Dominic PilonPatrick Lefebvre
Apr 1, 2017·Clinical Drug Investigation·Stephane CheungSunny Tsukazawa
Jun 9, 2017·JAMA Psychiatry·Jari TiihonenHeidi Taipale
Feb 24, 2018·CNS & Neurological Disorders Drug Targets·Maurizio Pompili, Andrea Fiorillo
Jan 22, 2019·Neuropsychiatric Disease and Treatment·Rosaria Di LorenzoChiara Piemonte